Back to Top

A new funding opportunity from the CIHR Institute of Cancer Research (CIHR-ICR) is available and provides up to $500,000 to use provincial data from the OHS, or to use pan-Canadian data from the Canadian Partnership for Tomorrow’s Health (CanPath). Up to $100,000 over one year will be awarded for a single grant. The goal of

Nicholas Cheng provides an overview of his study on identifying early cancer biomarkers in pre-diagnosis blood samples collected from more than 400 OHS participants. He demonstrates how blood signatures can be used to detect breast, prostate and pancreatic cancers years prior to clinical detection using cfDNA methylation profiles. Kimberly Skead describes her work studying how the interacting

Dr. Philip Awadalla, (National Scientific Director, CanPath; Executive Scientific Director, Ontario Health Study) discusses how data from large population health cohorts like CanPath can be harnessed to support research into COVID-19 such as the socioeconomic and mental health impact, as well as disease severity, infection rates, and mapping of where people are most likely to